

Special Issue

Advances in Treatment of Drug Addiction

Message from the Guest Editors

Drug addiction is a substantial problem in several countries. In the US, for example, more than 100,000 people died from drug overdose in the last twelve months. Opioid addiction is currently the causative drug in 75% of these overdoses. Other drugs such as cocaine or newly designed drugs are increasing too and sometimes dishabituatation is ineffective. Relapses in drug addiction are one of the primary problems in this disease due to the neurobehavioral changes that occur. Relapses can happen even after years of withdrawal. On the other hand, in recent years different research institutes have been developing trials with new treatments to help avoid relapses. Some of them are in phase II or III and are targeted to different neurocircuitry or systems (i.e., the extended amygdala) involved in stress, which is believed to be a key factor. Some new dosage forms are also being tested in dishabituatation. In this Special Issue we intend to compile new advances related to drug addiction, focusing on treatment and how to improve drug abusers' quality of life.

- drug addiction
- treatment
- withdrawal
- relapse
- pharmacokinetics
- stress
- dopamine
- noradrenergic system
- drug abuse

Guest Editors

Dr. Javier Navarro-Zaragoza

Department of Pharmacology, Faculty of Medicine, University of Murcia, 30100 Murcia, Spain

Dr. Pilar Almela

Department of Pharmacology, School of Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, 30100 Murcia, Spain

Deadline for manuscript submissions

closed (30 April 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/117886

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).